Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Current Assets (2020 - 2026)

Immuneering's Current Assets history spans 7 years, with the latest figure at $161.4 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 322.47% to $161.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $161.4 million, a 322.47% increase, with the full-year FY2025 number at $176.2 million, up 345.21% from a year prior.
  • Current Assets came in at $161.4 million for Q1 2026, down from $176.2 million in the prior quarter.
  • The five-year high for Current Assets was $229.1 million in Q3 2025, with the low at $27.7 million in Q2 2025.
  • Historically, Current Assets has averaged $103.4 million across 5 years, with a median of $100.6 million in 2023.
  • Peak annual rise in Current Assets hit 345.21% in 2025, while the deepest fall reached 56.47% in 2025.
  • Year by year, Current Assets stood at $108.7 million in 2022, then fell by 18.08% to $89.1 million in 2023, then plummeted by 55.56% to $39.6 million in 2024, then soared by 345.21% to $176.2 million in 2025, then dropped by 8.42% to $161.4 million in 2026.
  • Business Quant data shows Current Assets for IMRX at $161.4 million in Q1 2026, $176.2 million in Q4 2025, and $229.1 million in Q3 2025.